BOC Sciences, with its accumulated experience in liposome research, has developed a set of methods using liposomes as antigen carriers to prepare anti-low immunogenic vaccines.
For some molecules with very weak auto-immunogenicity, subdivision, glycolipids, multiples, DNA, etc., it is often difficult to achieve high specificity for the target antigen even using carrier interconnection methods to increase their immunogenicity. Liposomes have been regarded as a new type of adjuvant or vaccine implantation carrier due to their excellent antigen-stimulating activity.
Key Advantages of Liposome Vaccines
- Safety and tolerability
Since liposomes usually consist of lipids naturally present in cell membranes, such as PC and cholesterol, these formulations are fully biodegradable
Lipid components and vesicle preparation methods can be adjusted to achieve desired physicochemical properties for liposome formulations. Hydrophilic molecules can be encapsulated within the aqueous interior or bound to the surface of the vesicles, while hydrophobic compounds can be inserted into the lipid bilayer. This versatility allows the incorporation of all types of antigens, including peptides, proteins, carbohydrates, nucleic acids, and small molecules, into liposomal formulations, and the vesicle properties are modified to accommodate the size and charge of the antigen.
Figure 1: Intracellular processing of liposomal antigens
What We Provide?
BOC Sciences provides customers with professional and efficient liposome vaccine packaging services. For different antigens with low immunogenicity or even non-immunogenicity, we can adjust the size, potential and membrane composition of liposomes and increase their interaction with antigen-presenting cells (APC) to promote the development of vaccines.
- High quality raw materials
- Free design
- Experienced experts and professional technical support
- Strict QA and QC
- 1 on 1 customer service
- Competitive price
- Fast delivery
BOC Sciences liposome platform serves the global market. Contact us for more detail our capability on liposome formulation and encapsulation.
- Douglas S. Watson. et al. Design considerations for liposomal vaccines: Influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens. Vaccine. 2012 Mar 16; 30(13):2256-2272.
- Reto A. Schwendener. et al. Liposomes as vaccine delivery systems: a review of the recent advances. Ther Adv Vaccines. 2014 Nov; 2(6):159-182.